2020 ASCO Virtual Direct™ Highlights
2020 ASCO Update on mUC: Can We Consider Recently FDA Approved Avelumab Maintenance a New 1st-line SoC? Is Switch Maintenance Checkpoint Inhibition Preferred Over a Treatment Break Followed by 2nd Line?
By
2020 ASCO Virtual Direct™ Highlights
FEATURING
Russell Pachynski
By
2020 ASCO Virtual Direct™ Highlights
FEATURING
Russell Pachynski
Login to view comments.
Click here to Login
